// Current news

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-histidine from fermentative origin by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased to expand our CEP portfolio for regulated pharmaceutical applications.”, states Henrike Bertz, responsible for Regulatory Affairs at AMINO. “Histidine is one on the most uprising products of our broad product spectrum, hence we are very pleased that this amino acid is now CEP certified.”, adds Kai-Philipp Thomas, Marketing & Sales Director of AMINO GmbH.

L-Histidine is a semi-essential amino acid and is used in many pharmaceutical products and infant formula.

#seidnettzueinander is a campaign of the newspaper Braunschweiger Zeitung, in order to put the focus back on a respectful relationship with each other and to promote / enhance the understanding for each other.

Respect is one of the six corporate values ​​of AMINO GmbH. For this reason, we support the campaign of the Braunschweiger Zeitung, with which we show our colours for a more respect behaviour every day. Thus, AMINO sets an example for more politeness, gratitude and helpfulness within our society.

At the same time as the opening of the new Innovation Centre, the AMINO brand was sharpened and refined as part of a new communication strategy.

The modern logo symbolically combines the values of the company with the function of amino acids as the building blocks of life.

The six corporate values are thus reflected in the colour scheme of the logo. Each colour symbolises one of these values on which AMINO's self-image is based: Integrity, performance, communication, respect, responsibility and sustainability.

With the construction of a new innovation center AMINO sets the foundation for the next generation of products and services.

“In parallel to our existing business, i.e. the production of pharmaceutical- grade amino acids, we intend to develop amino acid derivatives and other APIs as well as diversify our production technology”, says Roman Erath, project manager of the new innovation center. “Furthermore we offer our customers development resources for joint projects”, explains Kai-Philipp Thomas, head of marketing & sales, the reasons for the strategic investment.

The construction of the research and development center for approximately € 4.2 Mio is partially co-funded by the NBank to support small and medium-sized enterprises. The new facility will provide ideal conditions for the development of technologies currently not available to AMINO, such as chemical synthesis and derivatization in combination with state-of-the-art methods of analysis. At present projects are underway in a laboratory scale. In the future those projects will be up-scaled to a pilot scale and successively transferred into production. The new innovation center creates a motivating environment for young scientific and technical talents to start their professional career.

“The AminoVation-Team is responsible for the design of the new center and organizes its workplace at their own discretion” outlines CEO Dr. Lutz Thomas an additional positive effect for the Company.

The AMINO GmbH reviews a strategic partnership with MH2 Biochemical Co., Ltd (Korea).

The South Korean company, founded in 2003, is a manufacturer of biochemical products focusing on D-amino acids and supplying customers within the health and cosmetic sector. Through a cooperation with MH2 AMINO aims to expand its product offering in order to promote its international growth strategy. “First we have to carry out negotiations with MH2 to see how a cooperation between the two companies could work,” says Dr. Lutz, Thomas, CEO of AMINO.
“In any event we are interested in integrating new products and technologies into our range of products and services.”

AMINO GmbH announces that a new subsidiary was established under the name of Amino Korea Co., Ltd. The registration of Amino Korea was executed and authorized in Seoul as of July 4, 2018. "Through this subsidiary, we aim to expand our pharmaceutical-grade amino acids business in Asia by enhancing partnerships with customers and suppliers in a timely and sustainable manner to accelerate our international growth strategy" said Dr. Lutz Thomas, CEO of AMINO GmbH.

Amino GmbH, which produces high-quality pharmaceutical-grade amino acids for pharmaceutical, medical and clinical dietetic nutrition applications, announces plans to double production capacity by building a new facility at its headquarters in Frellstedt, Germany. Amino is investing approximately $35 million to meet the growing demand of current customers and to increase supply and availability for the worldwide pharmaceutical and nutritional market. Construction will begin by March 31 and the new facility will begin operation in 2021.

“We are expanding because we believe in ourselves and we want to offer our services to a broader audience,” said Dr. Lutz Thomas, Managing Director.  “We will be an even stronger source for companies in the high-end pharmaceutical grade amino acid market.” 

Dr. Thomas said that by building the new facility, Amino will increase production by about 1200 metric tons across all product lines, the complete range of pharmaceutical grade amino acids. Serving Europe, Asia and the Americas, Amino specializes in amino acids for: infusions and injections; active pharmaceutical ingredients for oral applications; pharma-intermediates; pharmaceutical production in cell cultures, and medical nutrition and infant formula.

Amino has registered rapid and consistent annual growth for more than 10 years by adding value beyond the amino acid and helping customers solve their production problems.  To that end, Amino has invested heavily in R&D, creating its AminoVation platform to expand its line of products and services and respond even faster and more specifically to customers’ needs.

“We are developing the next generation of products for the next generation of employees and managers,” explained Dr. Thomas. “Building on our current portfolio we are developing amino acid derivatives and other APIs and nutrients.”

“Current growth is exhausting Amino’s production capacity.” said Dr. Thomas and added, “The Company now needs to think bigger and beyond its European base”.

“We plan to expand our marketing worldwide with a focus on the American markets,” said Kai-Philipp Thomas, Manager of Sales & Marketing.  “The new facility enables Amino to supply new customers, particularly pharmaceutical companies in the U.S., while also meeting increasing demand from our existing customer base.”

Immediately after the inauguration of the innovation center, the next project on the Amino premises was started: the construction of a new quality center.

"The current building for quality control and quality assurance limits the further development of our company," says Jörn Oetken, head of quality management and project manager for the new building. The new quality center will provide additional workplaces as well as modern laboratories encompassing the high requirements for quality control. Dr. Lutz Thomas, Managing Director of Amino GmbH, confirms: "The production of high-purity amino acids requires permanent quality assurance of all processes and quality control must be carried out in high-quality laboratories. With the construction of the new building, we create optimal conditions to support further growth of the company”. The investment for the quality center will be co-funded by the NBank.

In order to meet its customers expectations with regard to sustainable products and technologies as well as the compliance with ecological and social standards, AMINO publishes its sustainability report for the years 2016 to 2018.

The voluntarily published sustainability report will provide better transparency across the entire supply and value chain. "In addition to applying sustainable technologies, the objective of ensuring high ecological and social standards as the foundation of its economic success, people are within the focus of our activities." says CEO Dr. Lutz Thomas. Based on AMINO’s sustainability strategies clearly defined sustainability goals are set.

Download PDF document

After a construction period of 10 months and an investment volume of EUR 4.4 million, the new innovation center was inaugurated on 11.09.2019.

With the construction of the innovation center and the associated expansion of its research and development activities, AMINO intends to supplement the core business of the production of pharmaceutical amino acids with amino acid derivatives and other APIs as well as developing new technologies for the company.

"We offer our customers new development resources for joint projects," adds Kai-Philipp Thomas, Sales Manager of AMINO GmbH. The new building creates ideal conditions for the development of processes and technologies such as chemical synthesis or derivatization in combination with modern analysis methods. In the future projects which are currently being processed on a laboratory scale, can be scaled up to the pilot scale and then gradually transferred into the production. "The opening of our innovation center is an integral step of completing our growth strategy," explains Dr. Lutz Thomas, Managing Director of AMINO GmbH, after the successful opening ceremony.

EcoVadis is an independent platform for CSR reviews, on which companies can register the measures they take to implement corporate responsibility and have them reviewed.

“We are pleased by the positive recognition of our efforts to demonstrate sustainability and are motivated and committed to improve further” emphasizes Dr. Lutz Thomas, CEO of AMINO GmbH, the company’s future goals.

Great news for AMINO: The state of Lower Saxony, the Federal Government and the European Regional Development Fund have decided to grant financial support in the amount of EUR 1.8 Mio for the expansion of the company’s operational infrastructure and its utilities.

The Investment and Development Bank of Lower Saxony (NBank) thereby rewards the company’s commitment to invest into its facilities in Frellstedt in the district of Helmstedt. Within the next years AMINO plans to make an investment of EUR 9 Mio targeted at the construction of a research & development centre and the modernization of the site’s utilities infrastructure. The goal of the company is - according to Managing Director Dr. Lutz Thomas - to further increase the innovative power of the company and to strengthen the operations for the future.

AMINO and Hufort Healthcare Pvt. Ltd. have entered a new cooperation by signing a distribution and agency agreement.

Hufort, headquartered in Mumbay (India), specializes in the distribution and registration of active pharmaceutical ingredients. Hufort shall market, sell and distribute APIs manufactured by AMINO to Indian pharmaceutical customers.
“Working with Hufort Healthcare we allow us to access the Indian market, which holds an enormous potential for our company” says Dr. Shahid Iqbal Awan – the regional sales representative.

The AMINO GmbH was awarded by the German Stifterverband with the certificate “Innovative through Research” for its research and development activities. The association collects regularly R & D data in order to identify the innovation power of German companies in order to develop appropriate development programs. “Our AminoVation-team develops new products and sustainable processes for the company.” explains Dr. Lutz Thomas, CEO of AMINO GmbH. “As an innovative company we are happy about the appreciation.”

Together with its distribution partner IMCoPharma (Bílovec, Czech Republic) AMINO has successfully registered amino acids with the Ukrainian ministry for health.

The registration in Kiev enables AMINO to sell the amino acids in the Ukraine for pharmaceutical applications.
Dr. Lutz Thomas, CEO of AMINO, is pleased about the successful registration of the products and states: “Our strategy involves the international expansion of our target markets and this marks a big step in the right direction. Furthermore this strengthens our relationship with IMCoPharma.”